SCHEMBL8777624

SCHEMBL8777624

CC(C)(C)OC(=O)NCc1cccc(-c2ccc(S(=O)(=O)NC(C)(C)c3cnn[nH]3)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.41
CREBBP Q92793 1/20 0.41
HDAC1 Q13547 1/20 0.40
GLS O94925 3/20 0.38
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
NAMPT P43490 2/20 0.37
MMP1 P03956 2/20 0.37
MMP2 P08253 2/20 0.37
MMP3 P08254 2/20 0.37
MMP7 P09237 2/20 0.37
MMP10 P09238 2/20 0.37
MMP9 P14780 2/20 0.37
MMP8 P22894 2/20 0.37
MMP12 P39900 2/20 0.37
MMP14 P50281 2/20 0.37
MMP13 P45452 1/20 0.37
HPGDS O60760 1/20 0.37
CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8777128 0.90 GAA (0.45) HDAC1NAMPTMMP1MMP2MMP3
SCHEMBL8777638 0.90 MMP2 (0.40) NAMPTMMP1MMP2MMP3MMP7
SCHEMBL4793214 0.89 NAMPT (0.41) NAMPTMMP1MMP2MMP3MMP7
SCHEMBL5020142 0.89 MMP2 (0.43) HDAC1NAMPTMMP1MMP2MMP3
SCHEMBL4906501 0.88 PADI3 (0.38) HDAC1NAMPTMMP1MMP2MMP3
SCHEMBL5020145 0.87 NMT1 (0.37) NAMPTMMP1MMP2MMP3MMP7
SCHEMBL3095123 0.86 ADAMTS4 (0.44) MMP1MMP2MMP3MMP7MMP10
SCHEMBL3091364 0.85 AAK1 (0.43) ALDH1A1
SCHEMBL3091566 0.84 ROCK2 (0.46) MMP13HPGDSALDH1A1ROCK2
SCHEMBL3087406 0.84 CHRM3 (0.45) MMP1MMP2MMP3MMP7MMP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3483147-A1 METALLOENZYME INHIBITOR COMPOUNDS Innocrin Pharmaceuticals, Inc. (US) 2019-05-15 EP disclosed
US-20180221364-A1 METALLOENZYME INHIBITOR COMPOUNDS INNOCRIN PHARMACEUTICALS, INC. 2018-08-09 US disclosed
US-20140121248-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-05-01 US disclosed
US-8623892-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2014-01-07 US disclosed
US-20130184309-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2013-07-18 US disclosed
US-8389543-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2013-03-05 US disclosed
US-20120129886-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed
US-20100234378-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-09-16 US disclosed
US-20100234378-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234378-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS MMP3, MMP11, MMP13 BRD4 368/4885CREBBP 2465/4885HDAC1 55/4885
US-20140121248-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO BRD4 2327/4885CREBBP 2985/4885HDAC1 782/4885
US-20180221364-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO BRD4 2327/4885CREBBP 2985/4885HDAC1 782/4885
US-20130184309-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO BRD4 2327/4885CREBBP 2985/4885HDAC1 782/4885
US-20120129886-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO BRD4 2327/4885CREBBP 2985/4885HDAC1 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.